StockData

Curis vs Revolution Medicines

CRIS and RVMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRIS and RVMD compare

Revolution Medicines is the larger company, worth 30793 times as much as Curis ($34.9B against $1.1M).

Curis scores higher on the StockData Score (7 against 3 for Revolution Medicines), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRISRVMD
Size and price
Market cap$1.1M$34.9B
Share price$0.542$162.69
Change, 1 year−98.0%140%
Change, 5 years−100.0%502%
Beta (5Y)−0.102.75
Employees24883
StockData Score
Total score7 (better)3
Valuation score3 (better)0
Growth score01 (better)
Performance score00
Health score4 (better)2
Dividend score00
Valuation
P/S0.3×–
P/B0.2× (better)13.4×
FCF yield–−3.5%
Fair value$6.75–
Margin of safety92.0%–
Growth
Revenue growth (TTM)−62.2%–
Revenue growth, 5Y average−2.7%–
Profitability
Operating margin−203%–
Net margin−490%–
Return on equity–−79.1%
Financial health
Debt / equity0.00–
Interest coverage–−27.4×
Current ratio0.4911.38 (better)
Altman Z-score−96.1710.68 (better)
Piotroski F-score3 (better)2
Dividends and buybacks
Buyback yield−2171%–
Shareholder yield−2171%0.00% (better)
Ownership
Held by institutions32.1%105%
Held by insiders20.4%5.3%
Insider net buying, 12 months$5.5K (better)−$150M
Superinvestors holding–1
Short interest, % of float61.8%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.